Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: Implications for phosphodiesterase 3 inhibition in human cardiovascular tissues

Molecular Pharmacology

Volumn 58, Issue 2, 2000, Pages 247-252

  Palmer, Daniel ^a   Maurice, Donald H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION REGULATION; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; MORTALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TARGET CELL; TISSUE DISTRIBUTION; VASCULAR TISSUE;

EID: 0033916006     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.58.2.247     Document Type: Article

References (30)

1. Andrews R and Cowley AJ (1993) Phosphodiesterase inhibitors. Do the risks outweigh the benefits? Drug Safety 9:404-409.
2. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725-748.
3. Cuffe MS, Califf RM, Adams KF, Bourge RC, Colucci W, Massie B, O'Connor CM, Pina I, Quigg R, Silver M, Robinson LA, Leimberger JD and Georghiade M (2000) Rationale and design of the OPTIME CHF trial: Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J 139:15-22.
4. Degerman E, Belfrage P and Manganiello VC (1997) Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 272:6823-6826.
5. Erdogan S and Houslay MD (1997) Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem J 321:165-175.
6. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA and Phillips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702-3707.
7. Fisher DA, Smith JF, Pillar JS, St Denis SH and Cheng JB (1998) Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 246:570-577.
8. Johnson-Mills K, Arauz E, Coffey RG, Krzanowski JJ Jr and Poison JB (1998) Effect of CI-930 [3-(2H)-pyridazinone-4,5-dihydro-6-[4-(1H-imidazolyl)phenyl]-5-methyl- monohydrochloride] and rolipram on human coronary artery smooth muscle cell proliferation. Biochem Pharmacol 56:1065-1073.
9. Leroy MJ, Degerman E, Taira M, Murata T, Wang LH, Movsesian MA, Meacci E and Manganiello VC (1996) Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry 35: 10194-10202.
10. Liu H and Maurice DH (1998) Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: Differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125:1501-1510.
11. Macphee CH, Harrison SA and Beavo JA (1986) Immunological identification of the major platelet low-Km cAMP phosphodiesterase: Probable target for anti-thrombotic agents. Proc Natl Acad Sci USA 83:6660-6663.
12. Meacci E, Taira M, Moos M Jr, Smith CJ, Movsesian MA, Degerman E, Beifrage P and Manganiello VC (1992) Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phoaphodiesterase. Proc Natl Acad Sci USA 89:3721-3725.
13. Miki T, Taira M, Hockman S, Shimada F, Lieman J, Napolitano M, Ward D, Taira M, Makino H and Manganiello VC (1996) Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cyclic GMP-inhibited cyclic nucleotide phosphodiesterase family. Genomics 36:476-485.
14. Movsesian MA (1999) Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: Shifting the focus from inotropy to cyclic adenosine monophosphate. J Am Coll Cordiol 34:318-324.
15. Movsesian MA, Smith CJ, Krall J, Bristow MR and Manganiello VC (1991) Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 88:15-19.
16. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK and DeMets DL (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325:1468-1475.
17. Palmer D, Tsoi K and Maurice DH (1998) Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ Res 82:852-861.
18. Polson JB and Strada SJ (1996) Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol.36:403-427.
19. Rascon A, Lindgren S, Stavenow L, Belfrage P, Andersson KE, Manganiello VC and Degerman E (1992) Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle. Biochim Biophys Acta 1134: 149-156.
20. Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC and Bondy CA (1995) Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest 95:1528-1538.
21. Rose RJ, Liu H, Palmer D and Maurice DH (1997) Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br J Pharmacol 122:233-240.
22. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG and Beavo JA (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 100:2611-2621.
23. Sato N, Asai K, Okumura S, Takagi G, Shannon RP, Fujita-Yamaguchi Y, Ishikawa Y, Vatner SF and Vatner DE (1999) Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Am J Physiol 276: H1699-H705.
24. 2-adrenoceptor desensitization. J Biol Chem 273:20575-20588.
25. Smith CJ, Krall J, Manganiello VC and Movsesian MA (1993) Cytosolic and sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun 190:516-521.
26. Smith CJ, Huang R, Sun D, Ricketts S, Hoegler C, Ding JZ, Moggio RA and Hintze TH (1997) Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation 96:3116-3123.
27. Soderling SH, Bayuga SJ and Beavo JA (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553-15558.
28. Soderling SH, Bayuga SJ and Beavo JA (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 96:7071-7076.
29. Taira M, Hockman SC, Calvo JC, Taira M, Belfrage P and Manganiello VC (1993) Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem 268:18573-18579.
30. Zhao AZ, Zhao H, Teague J, Fujimoto W and Beavo JA (1997) Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA 94:3223-3228.